18 November 2026

Updated Securities Trading Policy

EVE Health Group Limited (**ASX: EVE**, **EVE** or the **Company**) advises that, in accordance with ASX Listing Rule 12.10, the Company provides its updated Securities Trading Policy, approved by the Board on 17 November 2026.

A copy of the Securities Trading Policy is attached to this announcement and is available on the Company's website.

This announcement was authorised for release by Steven Jackson, Chief Financial Officer.

Company enquiries
+61 8 6465 5500
info@evehealthgroup.com.au

About EVE Health Group
EVE Health Group (ASX: EVE) is an Australian life sciences company focused on developing and commercialising innovative pharmaceutical solutions in high-growth therapeutic areas. The Company's lead assets include Dyspro®, a fast-acting cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, and Libbo®, an oral dissolving film for erectile dysfunction designed to deliver rapid onset and improved patient convenience. Both products leverage EVE's proprietary formulation and delivery technologies to enhance bioavailability and clinical outcomes, representing near-term commercial opportunities in large, underserved global markets.

EVE is building a vertically integrated health platform that combines proprietary pharmaceutical products with digital education, patient engagement and prescribing pathways. Through its dedicated information platforms, ReclaimMyCycle.com (women's health) and LibX.com.au (men's health), the Company provides condition-focused education, reduces stigma and supports earlier engagement with appropriate care. These platforms integrate with telehealth and pharmacy fulfilment networks to enable responsible, scalable access to treatment within a regulated healthcare framework.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

SECURITIES TRADING POLICY

1. Introduction

This policy sets out the rules for buying and selling securities in the Company by its Key Management Personnel. It is designed to help Key Management Personnel avoid insider trading, and to meet the requirements of Listing Rules 12.9 to 12.12 of the ASX Listing Rules (**Listing Rules**).

Key Management Personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, directly or indirectly, including any Director (whether executive or otherwise), as defined in the Listing Rules. The Company has determined that its Key Management Personnel are its Directors, the Chief Executive Officer (**CEO**), the Chief Financial Officer, the Company Secretary, any employee reporting directly to the CEO, and any other person the Company Secretary notifies in writing.

Key Management Personnel are encouraged to be long-term holders of the Company's securities. However, care must be taken in the timing of any purchase or sale. In some respects, this policy goes beyond the strict requirements of the Corporations Act 2001 (Cth) (**Corporations Act**).

2. What is covered by this policy?

This policy applies to any purchase, sale or other dealing in the securities of the Company and its subsidiaries on issue from time to time, including shares, options, performance rights and any derivative over them (**Company Securities**). It applies to dealings made directly or through an Associate (see clause 3.3).

3. What is insider trading?

3.1. Prohibition

Insider trading is a criminal offence. It may also result in civil liability. In broad terms, a person will be guilty of insider trading if:

(a) that person possesses information which is not generally available to the market and, if it were generally available, would be likely to have a material effect on the price or value of Company Securities (**price sensitive information**); and

(b) that person:

(i) buys or sells Company Securities;

(ii) procures someone else to buy or sell Company Securities; or

(iii) passes on that information to a third party where that person knows, or ought reasonably to know, that the third party would be likely to buy or sell Company Securities or procure someone else to do so.

3.2. Examples

The following are examples of information that may be price sensitive:

(a) the Company considering a major acquisition, disposal or other material transaction;

(b) the Company's financial results materially exceeding (or falling short of) the market's expectations;

(c) a material change in debt, liquidity or cash flow;

(d) a significant product, research or regulatory development;

(e) the grant, loss or material change of a major contract;

(f) a proposed capital raising or share issue;

(g) the threat of major litigation against the Company; and

(h) a significant change in the Board, senior management or business structure.

3.3. Dealing through third parties

The insider trading prohibition extends to dealings through nominees, agents or other associates, such as family members, family trusts, family companies and self-managed superannuation funds (**Associates**).

3.4. Information however obtained

It does not matter how or where a person obtains the information. It does not have to come from the Company to be price sensitive information.

3.5. Securities in other companies

Buying or selling securities of another company is prohibited where a person has price sensitive information about that company. For example, a person who knows the Company is about to sign a major agreement with another company must not buy securities in either company.

4. Guidelines for trading in Company Securities

4.1. Closed Periods

Key Management Personnel must not, except as permitted by this policy, deal in Company Securities during the following periods (together, the **Closed Periods**):

(a) two weeks before, and 24 hours after, the release of the Company's quarterly activities report and Appendix 4C;

(b) two weeks before, and 24 hours after, the release of the Company's half-year report;

(c) two weeks before, and 24 hours after, the release of the Company's annual report; and

(d) two weeks before the lodgement of a prospectus or other disclosure document, until it closes for applications, except when applying for securities under it.

The Chair or the CEO may impose additional restrictions on trading at any time by notice to Key Management Personnel, for example while a material matter is being negotiated. The Company Secretary will endeavour to notify Key Management Personnel of each Closed Period.

Regardless of Closed Periods, a person who has price sensitive information must not deal in Company Securities at any time. If they come into possession of price sensitive information after placing an order that has not been filled, they must cancel it.

4.2. No short-term trading

Key Management Personnel should not engage in short-term or speculative trading in Company Securities.

4.3. Hedging and margin loans

Key Management Personnel must not hedge their exposure to unvested remuneration, or to Company Securities subject to a holding lock (section 206J of the Corporations Act). Margin loans or other arrangements using Company Securities as security require prior approval under clause 5.1.

4.4. Exceptions

Key Management Personnel may at any time, without approval under clause 5, provided they do not have price sensitive information:

(a) transfer Company Securities already held into a superannuation fund or other saving scheme of which they are a beneficiary;

(b) invest in, or trade units of, a fund or scheme (other than one investing only in Company Securities) where the assets are invested at the discretion of a third party;

(c) where they are a trustee, trade in Company Securities by that trust, provided they are not a beneficiary and any decision to trade during a Closed Period is made by the other trustees or investment managers independently of them;

(d) undertake to accept, or accept, a takeover offer;

(e) trade under an offer or invitation made to all or most security holders, such as a rights issue, security purchase plan, dividend reinvestment plan or equal access buy-back, where the timing and structure of the offer has been approved by the Board, including decisions about taking up or selling entitlements;

(f) acquire Company Securities under a bonus issue to all holders of the same class, or under an employee incentive scheme approved by the Board;

(g) exercise (but not sell securities following exercise of) an option or right under an employee incentive scheme, or convert a convertible security, where the final date for exercise or conversion falls during a Closed Period; and

(h) trade under a non-discretionary trading plan approved under clause 5, which was not entered into or amended during a Closed Period.

5. Approval and notification requirements

5.1. Approval requirements

(a) Any Key Management Personnel (other than the Chair) wishing to buy, sell or otherwise deal in Company Securities must obtain the prior written approval of the Chair (or, if the Chair is unavailable, the CEO) before doing so.

(b) If the Chair wishes to deal in Company Securities, the Chair must obtain the prior written approval of the CEO (or, if the CEO is unavailable, another Director) before doing so.

(c) The person giving approval is the **Approval Officer**. Approval by email is sufficient.

5.2. Requests and approvals

(a) A request must state the number of securities, whether the dealing is a purchase or sale, the registered holder and the estimated timeframe, and confirm that the person does not have price sensitive information.

(b) Approval will not be given if the Approval Officer considers that the person may have price sensitive information, or during a Closed Period except under clause 5.3.

(c) An approval is valid for 5 business days unless it states otherwise, and may be withdrawn if new information comes to light. The Approval Officer may refuse approval without giving reasons. A refusal is final and must be kept confidential.

(d) Copies of requests and approvals must be given to the Company Secretary before the dealing takes place. The Company Secretary will keep a register of them.

5.3. Trading during a Closed Period in exceptional circumstances

(a) Key Management Personnel who do not have price sensitive information may apply in writing to the Approval Officer for prior written approval to buy, sell or otherwise deal in Company Securities during a Closed Period where there are exceptional circumstances.

(b) Exceptional circumstances may include:

(i) severe financial hardship, where a pressing financial commitment cannot be met other than by selling Company Securities;

(ii) a court order, court enforceable undertaking (for example, in a bona fide family settlement) or other legal or regulatory requirement to transfer or sell Company Securities;

(iii) where the person's ability to deal has been restricted for an extended period because of consecutive Closed Periods or additional restrictions under clause 4.1; or

(iv) any other circumstance that the Approval Officer, after consulting at least one other Director, considers exceptional.

(c) The application must set out the relevant facts and attach supporting documents where applicable. Any approval must be in writing, state the period within which the dealing may occur and may be subject to conditions. The Approval Officer will notify the Board of any approval given. Exceptional circumstances approvals should be given sparingly and with caution.

5.4. Notification of dealings

Key Management Personnel must notify the Company Secretary in writing of any dealing in Company Securities (directly or through an Associate) within 2 business days of the dealing. This includes changes that do not arise from a trade, such as the issue, lapse, expiry or exercise of options.

6. ASX notification for Directors

The Listing Rules require the Company to notify ASX within 5 business days of any change in a Director's interests in Company Securities, and to disclose in the Appendix 3Y whether the dealing occurred during a Closed Period with prior written approval and, if so, the date of approval. The notification requirement in clause 5.4 forms part of the Company's arrangements with its Directors under Listing Rule 3.19B.

7. Breach, review and publication

(a) Compliance with this policy does not relieve any person of their obligations under the law, which must be the overriding consideration when dealing in Company Securities.

(b) A breach of this policy will be treated as serious misconduct and may result in disciplinary action, including termination of employment or engagement.

(c) The Board will review this policy periodically. Any material change will be given to ASX within 5 business days of taking effect, as required by Listing Rule 12.10. This policy will be published on the Company's website.